

Voting Questions for May 18 2023 VRBPAC

1. Are the available data adequate to support the effectiveness of immunization with ABRYSSVO during the second or third trimester of pregnancy (24-36 weeks gestational age) to prevent RSV lower respiratory tract disease [LRTD] and severe RSV LRTD in infants, from birth through 6 months of age?

Please Vote “Yes” or “No” or “Abstain”

2. Are the available data adequate to support the safety of immunization with ABRYSSVO during the second or third trimester of pregnancy (24-36 weeks gestational age) to prevent RSV LRTD and severe RSV LRTD in infants, from birth through 6 months of age?

Please Vote “Yes” or “No” or “Abstain”